Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix
- Thomas A. Paterniti(corresponding author),
- Katie Dorr,
- Asad Ullah,
- Joseph White,
- Hadyn Williams,
- Medical College of Georgia,
- ,
Abstract
BACKGROUND:Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive tumor treated with a combination of surgery, chemotherapy, and radiation. Survival rates are poor, and innovative therapies are needed.CASE:A 52-year-old woman was diagnosed with small cell neuroendocrine carcinoma of the cervix. Over a 10-year period, she was treated with six different systemic therapeutic regimens, underwent planned hysterectomy with bilateral salpingo-oophorectomy, and received radiation to the pelvis and brain. After a second recurrence of disease, she was treated with a combination of nivolumab and ipilimumab and experienced a complete and durable response.CONCLUSION:The combination of nivolumab and ipilimumab may represent a promising new treatment option for recurrent small cell neuroendocrine carcinoma of the cervix.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 813-816 (4 pages)Journal (Volume, Issue Number)
Obstetrics and gynecology (Volume 138, Issue 5)Publication milestones
- Published - 11/01/2021
Publication status
ISSN
0029-7844Publication IDs
- Scopus: 85120522838
- PubMed: 34619736